2026-10-05 · By SEPT AI
*By SEPT AI*
U.S. equities closed broadly higher on Monday, with technology and small-cap shares pacing gains as investors leaned into risk ahead of a busy stretch of corporate news. The Nasdaq-100 proxy QQQ led the major index trackers with a 0.91% advance to $756.20, while the S&P 500 proxy SPY added 0.69% to close at $774.98. The Dow proxy DIA lagged with a more modest 0.34% gain to $512.10, and the Russell 2000 proxy IWM rose 0.52% to $283.41.
The session's tone was set early and held throughout, with all four major proxies finishing in the upper half of their daily ranges. SPY touched a high of $776.61 against a low of $769.63, while QQQ printed a high of $756.92 and a low of $749.08. The Fear & Greed Index closed at 70, firmly in "Greed" territory, underscoring the market's constructive mood.
Technology and growth-oriented names drove the bulk of the upside, as reflected in QQQ's outperformance relative to the Dow and small-cap proxies. The strength was not confined to mega-cap tech, however. Biotechnology and small-cap healthcare names posted some of the day's most dramatic moves, with a cluster of FDA-related catalysts and licensing deals lifting the group.
Energy and consumer discretionary names faced headwinds. New Fortress Energy traded lower after disclosing a mechanical issue at its Fast LNG unit, and Camping World Holdings weighed on the consumer discretionary space after cutting its full-year EBITDA outlook. Financials and industrials were mixed, with merger news providing pockets of strength.
The day's most explosive move came from MI, which surged 130.10% to close at $6.88 on enormous volume of 137.2 million shares. The catalyst was not immediately detailed in available news, but the sheer volume suggests a major corporate development.
PDS Biotechnology (PDSB) jumped 56.05% to $1.20 on volume of 74.1 million shares after announcing the publication of Phase 2 trial results for PDS0101 in combination with pembrolizumab in JAMA Oncology. QTEX rose 20.75% to $1.58, and Novavax (NVAX) climbed 19.91% to $12.55 on volume of 27.2 million shares.
On the downside, SDEV plunged 59.68% to $3.91 on volume of 51.7 million shares. SSM fell 31.76% to $1.59, and Alector (ALEC) dropped 27.34% to $1.98 despite announcing an exclusive global licensing agreement granting Genentech worldwide rights to develop and commercialize its AL050 program — a reminder that dilution and deal terms can overwhelm positive headlines. Vaxcyte (PCVX) slid 15.20% to $73.95 after announcing a $500 million equity offering alongside a $500 million convertible notes offering.
Other notable gainers included DNA (+18.94% to $14.98), SPCM (+15.46% to $22.14), SPAL (+15.32% to $21.75), SPCF (+15.21% to $21.21), LOFF (+15.19% to $21.46), and Recursion Pharmaceuticals (RXRX), which rose 15.14% to $4.79 on volume of 64.7 million shares. AGM Group (AGMH) was halted on a circuit breaker to the upside, with the stock up 55.71% on short-squeeze dynamics.
Key Earnings
Two companies reported results. LOBO posted an EPS loss of $0.0735 on revenue of $14.59 million. PPCB reported an EPS loss of $1.38. Neither company provided comparable analyst estimates in the available data.
No economic data releases were reported in the session. However, corporate guidance and credit developments offered signals on the macro backdrop. Camping World Holdings said it expects FY26 adjusted EBITDA to fall below the low end of its previously communicated range of $230 million to $270 million, citing "continued uncertainty regarding macroeconomic conditions and RV industry demand." Separately, S&P downgraded Nike's credit rating from A+ to A with a negative outlook, pointing to a "protracted turnaround" and an expected steep decline in cash flows.
Merger and acquisition activity was a dominant theme. Option Care Health (OPCH) traded higher following reports that McKesson and Clayton Dubilier & Rice are nearing a deal to acquire the infusion services provider for more than $5 billion, according to the Financial Times. Polar Power (POLA) rejected Solidion's all-cash offer for all its assets as undervaluing the company, though it remains open to other deals. Solidion also refused to raise its bid for Flux Power (FLUX).
On the capital-raising front, dilution weighed on several names. YYForce (YFOR) fell after announcing a $20 million offering of Class A shares. authID (AUID) entered a $1.35 million private placement of convertible debentures and warrants. Spyre Therapeutics (SYRE) announced a proposed public offering of undisclosed size.
In licensing and contracts, Genmab (GMAB) rose after reporting Phase 3 EPCORE DLBCL-2 results showing epcoritamab plus R-CHOP improved progression-free survival and reduced the risk of disease progression or death by 51% versus R-CHOP alone. Rezolute (RZLT) gained after the FDA recommended a pre-BLA meeting following a preliminary review of Phase 3 sunRIZE data for ersodetug in congenital hyperinsulinism. Rezolve Ai (RZLV) rose on a global reseller agreement with Mastercard. Ondas Holdings (ONDS) bagged a $56 million precision weapons order. ECARX (ECX) closed a $266 million Flyme deal. HeartBeam (BEAT) received FDA Breakthrough Device Designation for its heart attack assessment system. Guardant Health (GH) announced COSMOS-MEL01 trial results showing 81% sensitivity for distant recurrence.
Bitmine (BMNR) bought 15,112 ETH as the stock hit what the company described as a make-or-break level, according to available news. No broader crypto price data was provided.
Investors will watch for follow-through in the biotech and small-cap complex after Monday's outsized moves, particularly whether MI can hold its gains on continued volume. The pipeline of public offerings — including Spyre Therapeutics and Vaxcyte's dual equity-and-convertible raise — will be closely monitored for pricing and demand. Nike's credit downgrade and Camping World's guidance cut will keep consumer and retail sentiment in focus. With the Fear & Greed Index at 70, the market enters Tuesday in a confident mood, but the breadth of dilution announcements and mixed M&A outcomes suggest selectivity remains essential.
Access real-time market data, AI analysis, dark pool activity, and options flow.
Start Free Trial